This inhibitor blocks the activity of several kinases including bcr-abl and c-kit and has been approved for chronic myeloid leukaemia and gastrointestinal tumors, but it proved scarcely effective against gliomas in a phase II trial against grade III gliomas that should be highly dependent on PDGFR [91]. The gene discussed is KIT; the disease is central nervous system cancer.